XtalPi Holdings has unveiled its annual performance report for 2025, marking a historic milestone by achieving annual profitability for the first time. This accomplishment positions it as the inaugural listed entity within the AI for Science sector on the Hong Kong Stock Exchange to report a profit. According to the report, the company's full-year revenue soared to RMB 803 million, reflecting a remarkable year-on-year increase of 201.2%. Its annual profit reached RMB 135 million, complemented by an adjusted net profit of RMB 258.2 million. By the end of 2025, XtalPi Holdings boasted a substantial cash balance of RMB 7.0686 billion, bolstered by a net influx of RMB 2.5368 billion from newly issued convertible bonds in 2026.

Both of XtalPi Holdings' primary business segments exhibited robust growth trajectories. Revenue from its drug discovery solutions surged to RMB 538 million, registering an impressive year-on-year leap of 418.9%. This surge was primarily fueled by the flourishing antibody business and the attainment of key milestones in the delivery of innovative pipeline projects. The client base generating revenue from this segment expanded by 62% year-on-year, encompassing several prominent international pharmaceutical firms.

The other core business, AI4S Smart Solutions, generated revenue of RMB 265 million, marking a year-on-year increase of 62.6%. This segment has successfully undergone a strategic transformation, evolving its business model into a platform-based facilitator.